Abstract:The health risks that arise from environmental exposures vary widely within and across human populations, and these differences are largely determined by genetic variation and gene-by-environment (gene–environment) interactions. However, risk assessment in laboratory mice typically involves isogenic strains and therefore, does not account for these known genetic effects. In this context, genetically heterogenous cell lines from laboratory mice are promising tools for population-based screening because they provide a way to introduce genetic variation in risk assessment without increasing animal use. Cell lines from genetic reference populations of laboratory mice offer genetic diversity, power for genetic mapping, and potentially, predictive value for in vivo experimentation in genetically matched individuals. To explore this further, we derived a panel of fibroblast lines from a genetic reference population of laboratory mice (the Diversity Outbred, DO). We then used high-content imaging to capture hundreds of cell morphology traits in cells exposed to the oxidative stress-inducing arsenic metabolite monomethylarsonous acid (MMA III ). We employed dose-response modeling to capture latent parameters of response and we then used these parameters to identify several hundred cell morphology quantitative trait loci (cmQTL). Response cmQTL encompass genes with established associations with cellular responses to arsenic exposure, including Abcc4 and Txnrd1 , as well as novel gene candidates like Xrcc2 . Moreover, baseline trait cmQTL highlight the influence of natural variation on fundamental aspects of nuclear morphology. We show that the natural variants influencing response include both coding and non-coding variation, and that cmQTL haplotypes can be used to predict response in orthogonal cell lines. Our study sheds light on the major molecular initiating events of oxidative stress that are under genetic regulation, including the NRF2-mediated antioxidant response, cellular detoxification pathways, DNA damage repair response, and cell death trajectories. Exposure to environmental toxicants leads to adverse health outcomes. Natural genetic variation regulates the likelihood and severity of these outcomes, but studying the underlying genes and pathways in human populations is challenging. Population-based rodent models simulate the genetic variation of the human population offering numerous advantages as experimental genetic models for studying gene–environment interactions and in chemical risk asessment. These include exquisite environmental control and higher power for mapping the genes and pathways that influence sensitivity and resilience to environmental exposures. We leveraged a genetically diverse laboratory mouse population to investigate the genetic regulation of arsenic response. To minimize animal use, cells were derived from each individual animal through a minimally invasive tail biopsy. These cells provide a reusable genetic resource for chemical or drug screening through which predictions of risk can be made and tested in genetically matched laboratory mice. To evaluate the utility of this resource, we used high content imaging to quantify changes in cell morphology following exposure to the arsenic metabolite MMA III . Using dose-response modeling, we identified the subset of morphological changes that are informative of arsenic response and that exhibit robust interindividual variation. We then used genetic association mapping to identify several hundred loci regulating individual differences in arsenic response. To nominate candidate driver genes, we integrated various lines of evidence from published arsenic studies and molecular data from the same mouse population. Our work demonstrates that genetic variation in the molecular pathways regulating arsenic transport, oxidative stress, and DNA damage contribute to variation in arsenic response. Additionally, we show that this genetic variation predicts cellular response in independent experiments. Our data establish a population-based approach for studying gene–environment interactions using inexpensive and high-throughput cell morphology traits in an experimental system that enables recursive in vitro and in vivo experimentation across genetically matched individuals.

A cellular genetics approach identifies gene-drug interactions and pinpoints drug toxicity pathway nodes

Quantitative High-Throughput Screening for Chemical Toxicity in a Population-Based in Vitro Model.

Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity

Chemical target and pathway toxicity mechanisms defined in primary human cell systems

Identifying Protein Features and Pathways Responsible for Toxicity Using Machine Learning and Tox21: Implications for Predictive Toxicology

Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens

Large-Scale Transcriptional Profiling of Molecular Perturbations Reveals Cell Line Specific Responses and Implications for Environmental Screening

Elucidation of differential response networks from toxicogenomics data

A network-based transcriptomic landscape of HepG2 cells uncovering causal gene-cytotoxicity interactions underlying drug-induced liver injury

Exploration of potential molecular mechanisms and genotoxicity of anti-cancer drugs using next generation knowledge discovery methods

Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics

Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms

Utilizing gene co-expression networks with the rat kidney TXG-MAPr tool to enhance safety assessment, biomarker identification and human translation

Deducing the mechanism of action of compounds identified in phenotypic screens by integrating their multiparametric profiles with a reference genetic screen

Analysis of the Chemical Toxicity Effects Using the Enrichment of Gene Ontology Terms and Kegg Pathways

Systematic Drug Safety Evaluation Based on Public Genomic Expression (connectivity Map) Data: Myocardial and Infectious Adverse Reactions As Application Cases.

Unraveling the genetics of arsenic toxicity with cellular morphology QTL

Toxicogenomics and drug discovery: will new technologies help us produce better drugs?

Pre-Clinical Drug Prioritization Via Prognosis-Guided Genetic Interaction Networks

Differential Reconstructed Gene Interaction Networks for Deriving Toxicity Threshold in Chemical Risk Assessment.

Application of genomics in preclinical drug safety evaluation.